170838-40-1

Usage

Chemical structure

A complex chemical compound with a tetrahydropyridine ring, a phenyl group at the 4-position, a carboxylic acid group at the 3-position, and a tert-butoxycarbonyl (Boc) protecting group attached to the nitrogen atom.

Phenyl group

A benzene ring with six carbon atoms and delocalized pi electrons, attached at the 4-position of the tetrahydropyridine ring.

Carboxylic acid group

A functional group consisting of a carbonyl group (C=O) and a hydroxyl group (-OH) attached to the 3-position of the tetrahydropyridine ring.

tert-Butoxycarbonyl (Boc) protecting group

A bulky protecting group (tert-butyl ester) attached to the nitrogen atom of the tetrahydropyridine ring, which can be removed under specific conditions to reveal the free amine.

Precursor in organic synthesis

Often used as a starting material in the preparation of pharmaceuticals and other biologically active compounds.

Versatile nature

The compound's structure allows for various synthetic modifications, making it of interest to synthetic chemists and researchers in the pharmaceutical industry.

Boc group removal

The Boc protecting group can be removed under specific conditions (e.g., using an acid or a strong base) to generate the free amine, which is useful in the construction of complex molecules.

Applications

Used in the development of pharmaceuticals and other biologically active compounds due to its ability to be modified and serve as a versatile building block in organic synthesis.

Upstream product

• 170837-88-4 1-tert-butyl 3-ethyl 4-triflate-5,6-dihydropyridine-1,3(2H)-dicarboxylate 
• 98977-34-5 1-tert-butyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 161491-25-4 1-tert-butyl 3-methyl 4-(((trifluoromethyl)sulfonyl)oxy)-5,6-dihydropyridine-1,3(2H)-dicarboxylate 
• 161491-24-3 methyl 1-tert-butoxycarbonyl-4-oxo-3-piperidinecarboxylate 
• 221141-77-1 1-tert-butyl 3-methyl 4-phenyl-5,6-dihydropyridine-1,3(2H)-dicarboxylate 
• 176525-98-7 1-(1,1-dimethylethyl) 3-ethyl 4-{[(trifluoromethyl)sulfonyl]oxy}-1,2,5,6-tetrahydropyridine-1,3-dicarboxylate 

Downstream Products

• 197900-77-9 (3S,4S)-cis-N-(tert-butoxycarbonyl)-4-phenyl-3-carboxypiperidine 
• 197900-84-8 (3R,4R)-cis-N-(tert-butoxycarbonyl)-4-phenyl-3-carboxypiperidine 

Relevant academic research and scientific papers

NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND

The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt: [wherein, R1 represents optionally substituted C1-4 alkyl, n shows integer of 1 to 4, R2 represents optionally substituted C1-4 alkyl or hydrogen atom, R3 represents optionally substituted C1-4 alkyl, R4a, R4b, R4c, and R4d, similarly or differently, represent optionally substituted C6-14 aryl, optionally substituted C1-4 alkyl, or hydrogen atom and the like, A represents optionally substituted C6-14 aryl or optionally substituted 5 to 11 membered heteroaryl].

Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists

The M5 muscarinic acetylcholine receptor is suggested to be a potential pharmacotherapeutic target for the treatment of drug abuse. We describe herein the discovery of a series of M5-preferring orthosteric antagonists based on the scaffold of 1,2,5,6-tetrahydropyridine-3- carboxylic acid. Compound 56, the most selective compound in this series, possesses an 11-fold selectivity for the M5 over M1 receptor and shows little activity at M2-M4. This compound, although exhibiting modest affinity (Ki = 2.24 μM) for the [3H]N-methylscopolamine binding site on the M5 receptor, is potent (IC50 = 0.45 nM) in inhibiting oxotremorine-evoked [3H]DA release from rat striatal slices. Further, a homology model of human M5 receptor based on the crystal structure of the rat M3 receptor was constructed, and docking studies of compounds 28 and 56 were performed in an attempt to understand the possible binding mode of these novel analogues to the receptor.

Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety

The present invention relates to trans-derivatives of formula wherein R1, R2, R3, and the dotted line are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are goo

Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids

The present invention relates to a process for the preparation of cis substituted cyclic β-aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme w